Navigation Links
Clinical trial demonstrates that rilonacept significantly reduces gout flares
Date:1/4/2012

A phase II clinical trial found that rilonacept, an inhibitor of the protein interleukin-1 (IL-1), significantly reduced acute gout flares that occur when initiating uric acid-lowering therapy. Results of the trialthe first placebo-controlled study investigating IL-1 targeted therapy in prevention of gout flaresshow rilonacept to be generally well tolerated with no serious infections or treatment-related serious adverse events reported. Full findings are published in Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).

Patients with gouta type of inflammatory arthritis caused by the crystallization of urates in soft tissuesexperience severe pain and swelling, often affecting the feet. A recent study also published in Arthritis & Rheumatism reported that doctor-diagnosed gout has risen over the past twenty years and now affects 8.3 million individuals in the U.S. Previous research shows that while gout attacks typically resolve spontaneously over several days, urate crystals remain in the joint, which can lead to recurrent attacks and if left untreated may permanently damage joints.

"To reduce deposits of crystals in the joints, we advise patients to initiate treatment with medications that lower levels of uric acid in the blood," said lead investigator Dr. H. Ralph Schumacher, Jr., Professor of Medicine at the University of Pennsylvania School of Medicine. The authors explain that in the early months of urate-lowering therapy, as crystal deposits are broken up, patients may experience gout attacks that are proposed to be due to the release of crystals from softened deposits. These urate crystals interact with cells that release interleukin-1 (IL-1) which can lead to a cascade of inflammation and acute joint pain flares.

Previous research has found that acute gout attacks brought on by uric acid-lowering therapy may make patients less likely to continue treatment. "Well tolerated drugs that reduce the risk of gout flares when initiating uric-acid lowering therapy could make patients more likely to continue important long-term treatments that control gout," added Dr. Schumacher.

Rilonaceptmarketed under the brand name ARCALYST to treat another diseaseis designed to neutralize the protein IL-1 before it produces signals that can trigger inflammation. Thus, researchers looked to test the effectiveness of rilonacept in preventing gout flares and enrolled 83 patients at 27 study centers across the U.S. for a phase II clinical trial. Participants were 18 years of age or older and had gout, including a history of two or more gout flares within the prior year, as well as elevated blood levels of uric acid. Participants were randomized in a double blind fashion, with 41 administered rilonacept via subcutaneous injection (a double dose [320 mg], followed by (160 mg weekly for 16 weeks) and 42 administered weekly placebo. All patients were started on allopurinol (300mg/day) to reduce uric acid levels.

Trial results revealed a significantly lower number of gout flares in participants taking rilonacept with only 6 flares in the rilonacept arm compared with 33 in the placebo group. Researchers also observed fewer flares in patients treated with rilonacept as early as four weeks following the start of therapy. At the 12-week study point, only 15% of patients taking rilonacept had experienced gout flares compared to 45% of those in the placebo group. No deaths or serious infections occurred in either group. Common adverse events included infections reported in 15% of the rilonacept group compared with 26% with the placebo.

"This trial provides well-controlled evidence that this IL-1 blocker is effective in preventing acute gout flares in this setting," confirmed Dr. Schumacher. "Rilonacept appears safe and well tolerated and could increase patient adherence to long-term urate-lowering therapy." The authors recommend further evaluation of rilonacept in patients with gout.


'/>"/>
Contact: Dawn Peters
healthnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Stethoscope App gives iPhone New Clinical Skills
2. Sunquest Introduces Integrated Clinical Environment Physician Portal Solution in US
3. Almac Launches New STEMS System to Transform Temperature Controlled Shipment Monitoring in Clinical Trials
4. Clinical trial underway: Miniature ultrasound device could revolutionize pain relief
5. Michael J. Fox Foundation Awards $1.1 Million For Clinical Trial of Transdermal Nicotine as Disease-Modifying Treatment For Parkinsons
6. NOVAVAX Presents Positive Clinical Results at The World Health Organization Conference, Geneva, Switzerland
7. UCLA Health System Presents: How to Successfully Implement a Clinical Portal
8. TeraMedica Launches Evercore – Clinical Enterprise Suite 5.0 Now on Linux
9. Mesothelioma Clinical Trials List Offered by IQ Mesothelioma: Search Current Mesothelioma Treatment Options
10. MedQuist Launches EHR Integration for Dictations Associated with Template-based Clinical Documentation
11. Greenway Medical Technologies Donates Electronic Health Record, Clinical Research and Revenue Cycle Solutions to Northern Kentucky University
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Melanoma is the deadliest type of skin cancer. Although ... the majority of skin cancer deaths. More than 10,000 people are expected to die of ... is 62, it is the one of the most commonly diagnosed cancers in young women. ...
(Date:4/29/2016)... ... , ... For those who skip meals occasionally (which is pretty much everyone), ... many new lifestyle diet tips offered by nutritionists Pam Bonney and Priya Lawrence of ... show. Bonny and Lawrence noted that because proper nutrition, including water, provides energy during ...
(Date:4/29/2016)... ... April 29, 2016 , ... CURE Media ... on patients with cancer, today announced that Lynne Malestic, RN, of Eisenhower Lucy ... CURE® Extraordinary Healer® for Oncology Nursing , which honors nurses who have dedicated ...
(Date:4/29/2016)... ... April 29, 2016 , ... International Dehydrated Foods, Inc. (IDF™) will attend and ... at the Doubletree by Hilton Hotel in Oak Brook, Illinois. The two-day event is ... for protein ingredients. , At the seminar, IDF™ will offer samples of its Savory ...
(Date:4/29/2016)... ... April 29, 2016 , ... Intellitec Solutions ... May 16th to 18th at the Broward County Convention Center. The event is ... collaborate on best practices in public facility management. Intellitec Solutions will highlight their ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... YORK , April 28, 2016  The blood ... 275 million dollars, according to Kalorama Information and The ... typing, immunoassays and nucleic acid testing.  The healthcare research ... made progress in developing blood collection stations and in ... made in Kalorama Information,s report, Blood Testing ...
(Date:4/28/2016)... , Net Sales of $1.90 billion represent an increase ... period, and an increase of 1.2% on an adjusted pro ... first quarter were $0.52 reported, a decrease of 47.5% from ... 29.9% over the prior year period , The Company ... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) ...
(Date:4/28/2016)... JERUSALEM , April 28, 2016 ... ), a clinical-stage pharmaceutical company focused on the development of ... participate in the upcoming PIONEERS 2016 conference, presented by ... 5, 2016 in New York . ... overview at the conference. Presentation Details:   ...
Breaking Medicine Technology: